IN CYSTIC FIBROSIS (CF), mutations of the gene coding for the CF transmembrane conductance regulator (CFTR) Cl
Ϫ channel cause dysfunction of Cl Ϫ secretion, resulting in unbalanced Cl Ϫ , Na ϩ and fluid transport, thus reducing mucociliary clearance and favoring bacterial colonization and chronic inflammation in airways. The persistence of oxidants, proteases, and inflammatory mediators is central to the progression of lung damage and remodeling as well as the decline of lung function in patients with CF (for review see Refs. 17 and 52) . Severe bronchiectasis is the most commonly observed structural abnormality in CF lungs. However, ultrastructural studies have also disclosed nonspecific ciliary anomalies, goblet and basal cell hyperplasia, squamous cell metaplasia, and decreased Clara cells (21, 30, 52) .
In response to injury, epithelial tissues initiate repair processes in an attempt to restore the normal airway architecture. However, these processes seem ineffective in reestablishing epithelial integrity in patients with CF. It is not yet clear whether this inefficient repair is attributable to a basic repair default of CF airways (28, 56) , to the severity of epithelial damage induced by infectious and inflammatory products, or to inflammation itself affecting the ability of CF airways to repair themselves. It is thus important to further study the regulatory mechanisms of airway epithelial repair by inflammatory cytokines. To date, it has been determined that epithelial repair involves multiple mechanisms, including 1) dedifferentiation, 2) adhesion/de-adhesion to the extracellular matrix (ECM) controlled by integrins and matrix metalloproteinases (MMPs), 3) spreading and migration of healthy cells, 4) cell proliferation, and 5) redifferentiation (49) . These processes are modulated by several growth factors, including epidermal growth factor (EGF), through EGF receptors (EGFR), a convergent pathway producing motility and proliferative responses (32, 52, 57, 58) . We have recently demonstrated the involvement of an autocrine EGF loop in the control of non-CF (NuLi) and CF (CuFi) bronchial repair processes (58) . Moreover, K ϩ channel function, particularly KvLQT1, K ATP , and KCa3.1, coupled with EGFR signaling, was found to be crucial for epithelial repair (58) . Our study also highlighted a delay in repair of CuFi compared with NuLi monolayers, associated with reduced K ϩ channel function and a lower EGF response in CuFi cells (58) . Although EGF is key in bronchial repair, several other growth factors and inflammatory mediators might also regulate airway regeneration.
Chronic inflammation of lung tissue is a hallmark of CF lung physiopathology, and elevated levels of various proinflammatory cytokines are detected in CF airways (17, 35, 37) . Among them, tumor necrosis factor-␣ (TNF-␣) is a pivotal component of inflammation initiation and progression (35) . Thus it is both beneficial in developing immune responses but also deleterious through amplification of inflammatory reactions and neutrophilic infiltration, leading to epithelial injury. TNF-␣ could also have opposing effects on repair mechanisms. For example, pro-(2, 15) and antiproliferative (6) actions of TNF-␣ as well as promigratory outcomes (15) have been reported in epithelial cells. Secondary activation by TNF-␣ of metalloproteinases [MMPs and a disintegrin and metalloproteases (ADAMs)] (2, 15, 65), which have been demonstrated to evoke EGFR ligand shedding in many cell types (8, 29, 33, 43, 64) , could also induce the EGFR pathway (2, 15, 62) . However, the impact of TNF-␣ on repair processes and the relationship between the TNF-␣ response and EGFR signaling in CF airways have never been defined. Finally, K ϩ channels have been shown to be up- (22, 60, 61) or downregulated (60) by TNF-␣, depending on the K ϩ channel subtype and cell type. To the best of our knowledge, the influence of TNF-␣ on lung K ϩ channels, involved in airway epithelial repair (58) , has never been studied.
Our aim was thus to investigate the effects of acute and chronic exposure to TNF-␣ on the repair processes of NuLi and CuFi bronchial monolayers. Our results indicated that cell growth during repair was reduced by TNF-␣, whereas cell migration and wound-healing rates were stimulated. We also evaluated the role of MMP and EGFR transactivation in TNF-␣-induced wound healing. In addition, because K ϩ channel activity is critical for bronchial repair, we examined coupling between TNF-␣ stimulation and K ϩ channel function. Finally, the physiological impact of TNF-␣ on wound repair of human primary non-CF and CF cell monolayers was assessed.
MATERIALS AND METHODS
Cell culture. NuLi-1 (non-CF) and CuFi-1 (CF, homozygote ⌬F508/⌬F508) bronchial cells, gifted by Dr. J. Zabner, were used between passages 13 and 17 to avoid any phenotypic drift, as established originally (63) . The cells were cultured in bronchial epithelial cell growth medium (BEBM; Lonza, Walkersville, MD) supplemented (BEGM ϩEGF ) with hydrocortisone, bovine pituitary extract (BPE), transferrin, bovine insulin, triiodothyronine, epinephrine, retinoic acid, penicillin-streptomycin, geneticin, fluconazole, and EGF (0.5 ng/ml), in human collagen type VI (Sigma-Aldrich, St. Louis, MO)-coated Petri dishes (58) . Some experiments were performed in the absence of EGF (BEGM EGF-free ) and/or BPE (BEGM EGF-BPE-free ). For short-circuit current (Isc) studies in an Ussing chamber, cells were cultured on collagen VI-coated permeant filters (Costar Transwell, Toronto, ON) in DMEM/F-12 (GIBCO, Invitrogen, Grand Island, NY), supplemented with UltroserG (increasing ion transport, 2%; Biosepra, Cergy-SaintChristophe, France), at the air-liquid interface (58) .
Primary human airway epithelial cells were recovered after nasal polypectomy procedures at CHUM-Hôtel-Dieu (Montréal, Québec, Canada), according to an approved ethics protocol. After dissection, polyps were rinsed with PBS and then incubated with MEM (Invitrogen) supplemented with 7.5% NaHCO 3 (Sigma-Aldrich), 2 mM L-glutamine, 10 mM HEPES (Fisher, Nepean, ON, Canada), 0.05 mg/ml gentamycin, 25 U/ml penicillin-streptomycin, 0.25 g/ml Fongizone (Invitrogen, Burlington, ON, Canada), 0.1% pronase E (Sigma-Aldrich), and 10 g/ml DNAse (Sigma-Aldrich), overnight, at 4°C, under gentle agitation. After neutralization of pronase-DNAse activity with 10% FBS, the cells were gently scraped off the remaining tissue, and the cell suspension was recovered and centrifuged for 5 min at 1,500 revolution/min. The cell pellet was resuspended with 5 ml ACK lysis solution (0.1 mM NH 4Cl, 10 M KHCO3, 10 nM EDTA), incubated on ice for 5 min and then neutralized with 10% FBS. After cell suspension centrifugation, the cell pellet was resuspended, counted, and seeded on supports coated with Purecol (Cedarlane, Burlington, ON, Canada). The cells were grown in CnT17 medium (CellnTec Advanced Cell Systems, Bern, Switzerland) until confluence and then in complete SAGM (LHC basal medium supplemented with SAGM) (Clonetics, Walkersville, MD) and 25 ng/ml EGF, 100 U/ml of penicillin-streptomycin, 0.07 g/ml phosphorylethanolamine (Sigma-Aldrich), 1.86 ng/ml ethanolamine (SigmaAldrich), 0.05 nM retinoic acid (Sigma-Aldrich), and stock 11, stock 4 and trace elements (kindly provided by Dr. Scott Randell, University of North Carolina).
Wound healing. NuLi, CuFi, and human primary cell monolayers were injured mechanically with a P10 pipette tip (6 wounds per Petri dish, 2 Petri dishes per condition) (58) , then washed to remove detached injured cells. The mean area of the initial wounds was 0.987 Ϯ 0.005 mm 2 , with maximal variation of 5%, demonstrating the reproducibility of our scratch assay (57, 58) . The monolayers were photographed with a digital camera under light microscopy (ϫ4 enlargement) at time 0 and after 6 h in BEGM ϩEGF or 18 h in BEGM EGF-free . A mark on the Petri dishes allowed us to photograph the wounds exactly at the same place at various times and to measure, with ImageJ software, the wound area initially and after repair. Our results are reported as repair rates in m 2 /h and compared with the outcome of different treatments (TNF-␣, BioSource; Invitrogen, Carlsbad, CA), GM6001 (USBiological, Swampscott, MA), anti-EGF antibody (EGF-Ab; Santa Cruz Biotechnology, Santa Cruz, CA), inhibitors of erbB1 (tyrphostin AG-1478) and erbB2 (tyrphostin AG-875), clofilium (a KvLQT1 channel blocker), glibenclamide (a K ATP channel blocker), and TRAM-34 (a KCa3.1 channel blocker) (Sigma-Aldrich) in BEGM ϩEGF or BEGM EGF-free . Cell proliferation. Cell proliferation was evaluated by counting NuLi and CuFi cell number 1) before injury, 2) at time 0 after injury, and 3) after 24 h of repair. Briefly, after culture in BEGM ϩEGF until confluence, the monolayers were washed with PBS, and the cells were separated with 0.25% trypsin-EDTA and then counted with an hemocytometer. The same method was employed to count the number of remaining cells at time 0 after injury in NuLi and CuFi monolayers (treated or not with TNF-␣ after injury, in BEGM EGF-free ) and after 24 h of repair (in the presence or absence of TNF-␣, in BEGM EGF-free ). The absence of cytotoxicity by TNF-␣ was verified by counting the number of detached cells as well as stained cells in Trypan-blue exclusion assay.
Single-cell tracking of cell migration in time-lapse experiments. The migratory capacity of NuLi and CuFi cells was evaluated by single-cell tracking in live time-lapse experiments after wounding. Confluent monolayers were treated or not for 48 h with TNF-␣ (in BEGM ϩEGF ) before injury (wound width was reduced to one-third of the standard wound size to reduce the duration of these experiments and focus on cell migration). Images were captured at 2-min intervals over a 60-min period by digital camera connected to an Olympus microscope (ϫ10 enlargement). Image J software was used to track single cells (30 individual EGF shedding. NuLi and CuFi cells were cultured until confluence in BEGM ϩEGF . Cell monolayers were then treated or not with TNF-␣ in BEBM for 24 h before conditioned medium collection. After centrifugation, the supernatants were concentrated on Amicon Ultra 3K filters (Millipore, Carrigtwohill, Ireland) and separated on 15% polyacrylamide-SDS gel. Pro-EGF and mature EGF bands were revealed by an EGF antibody (Santa Cruz Biotechnology). EGF band intensity, normalized by the pro-EGF signal, was quantified with Multigauge software and presented as a percentage of the control, nontreated condition.
Gelatin zymography analysis. NuLi and CuFi cell monolayers were wounded or not, and the medium was replaced by BEGM EGF-BPE-free supplemented or not with TNF-␣ and/or GM6001 for 24 h before conditioned medium collection. After centrifugation, the supernatants were concentrated on Microsep 10K Omega filters (Pall, Ann Arbor, MI) and then separated on 7.5% polyacrylamide-SDS gel containing 0.1% gelatin. The gel was washed for 1 h at room temperature in a 2% Triton X-100 solution and incubated in buffer containing 50 mM Tris·HCl, 0.1% Triton X-100, 5 mM CaCl 2 (pH 7.6), overnight at 37°C under gentle stirring. The gel was stained for 30 min in a 0.1% Coomassie blue (Sigma), 40% methanol, and 10% acetic acid solution and washed for 18 h in a buffer containing 10% acetic acid and 20% methanol for destaining. Finally, the gel was transferred to a solution of 10% acetic acid and 5% glycerol before drying. Signal intensity was analyzed by Multigauge software.
Transepithelial short-circuit ion currents in Ussing chamber. Transepithelial ion currents through NuLi and CuFi cell layers was studied by short-circuit current (I sc) measurement in an Ussing chamber (40, 58) . Cells were cultured on filters until they reached the air-liquid interface and formed a polarized epithelium with high resistance (Ͼ1,200 ⍀·cm 2 ). The filters were then treated or not (on the basolateral side) with TNF-␣, 24 h before the experiment. After being washed, the filters were mounted in a heated Ussing chamber and bathed with warm physiological solution.
Statistics. Experiments on NuLi and CuFi cells were conducted in parallel, in control and TNF-␣ conditions (paired experiments), and repeated a number of times (on different passages) indicated in each figure legend. The data are reported as means (of these repeat experiments) Ϯ SE. Groups were compared by paired or one-group t-test (as indicated in each figure legend) with Statview software (SAS Institute, Cary, NC). Probability of P Ͻ 0.05 was considered to be significant.
RESULTS

Impact of TNF-␣ on basal and EGF-stimulated bronchial wound healing.
The repair processes of NuLi and CuFi epithelia were studied in our model (58) of mechanical wound injury. We first confirmed (58) that the wound-healing rate in CuFi (25.9 Ϯ 4.0 ϫ 10 3 m 2 /h) monolayers was slower than in NuLi (72.2 Ϯ 8.1 ϫ 10 3 m 2 /h) monolayers in complete BEGM containing 0.5 ng/ml EGF (BEGM ϩEGF , Fig. 1A ). The impact of TNF-␣ (40 ng/ml in BEGM ϩEGF , applied at T0 after injury) on wound closure was then tested in NuLi and CuFi monolayers over a 6-h period (Fig. 1A) . We first verified that this TNF-␣ concentration elicited no cytotoxicity, evaluated by counting detached cells and by the Trypan blue exclusion test. We observed that TNF-␣ exposure, in the presence of EGF, slightly but not significantly affected the NuLi and CuFi wound-repair rates (Fig. 1A) .
In the absence of exogenous EGF stimulation (i.e., BEGM ϩEGF replaced by BEGM EGF-free at T0 after injury, Fig.  1B ), we noted that NuLi and CuFi wound closure rates were 2.5-and 1.4-fold slower, respectively, than in BEGM ϩEGF (compare control conditions in Fig. 1, A and B) . These results confirmed our previous findings showing the involvement of EGF in bronchial repair and the lower response to EGF in repairing CuFi cells (58) . Furthermore, a 5 ng/ml TNF-␣ concentration significantly stimulated the repair rate of NuLi (25.9 Ϯ 3.9 ϫ 10 3 m 2 /h in the control condition to 35.3 Ϯ 4.6 ϫ 10 3 m 2 /h in the presence of TNF-␣, n ϭ 9, P Ͻ 0.01) and CuFi (16.8 Ϯ 2.0 ϫ 10 3 and 25.6 Ϯ 2.9 ϫ 10 3 m 2 /h in control and TNF-␣ conditions, respectively, n ϭ 9, P Ͻ 0.003). TNF-␣, at 40 ng/ml (in BEGM EGF-free , applied at T0 after injury) elicited a higher stimulatory effect. Indeed, it enhanced the wound-repair rate in both NuLi (from 25.9 Ϯ 3.9 ϫ 10 3 m 2 /h in the absence of TNF-␣ to 43.6 Ϯ 3.7 ϫ 10 3 m 2 /h in its presence, n ϭ 9, P Ͻ 0.002) and CuFi (from 16.8 Ϯ 2.0 ϫ 10 3 m 2 /h to 28.1 Ϯ 2.6 ϫ 10 3 m 2 /h, P Ͻ 0.0001) monolayers (Fig. 1B) .
Stimulation of bronchial wound repair by chronic TNF-␣ treatments. Given that CF airways are chronically exposed to TNF-␣, we evaluated the effect of longer TNF-␣ treatments. The acute action of TNF-␣, applied at T0 after injury (protocol 1, TNF-␣-T 0 , Fig. 2A ), was compared with chronic treatment for 24 h (protocol 2, TNF-␣-T -24h ) and 48 h (protocol 3, TNF-␣-T -48h ) before injury. The TNF-␣-induced repair rate was compared with control, untreated monolayers, in the presence (BEGM , P Ͻ 0.0001) with 48-h pretreatments (Fig. 2B, n ϭ 6 ). In the absence of EGF (Fig. 2C) , chronic exposure to TNF-␣ also had a greater effect (1.89-and 2.52-fold stimulation with 24-and 48-h pretreatments, n ϭ 7, P Ͻ 0.05) on the NuLi wound-repair rate than acute treatment (1.39-fold stimulation, P Ͻ 0.003, Fig. 2C ). Similar results were obtained for the CuFi wound-healing rate that was enhanced by 2.56-and 2.74-fold after 24-and 48-h TNF-␣ pretreatments (n ϭ 6, P Ͻ 0.03) compared with control CuFi monolayers (Fig. 2C) .
Regulation of bronchial cell proliferation and migration by TNF-␣ during repair.
To further investigate the mechanisms involved in TNF-␣-enhanced repair, we evaluated the effect of TNF-␣ on cell growth and migration, the first cellular processes engaged during wound healing in our in vitro assay as well as during epithelial regeneration in vivo (48, 49) . Cell proliferation during repair was assessed first. A mean of 2.3 Ϯ 0.3 ϫ 10 6 cells was counted in NuLi and CuFi monolayers before wounding. Monolayer wounding resulted in a 25% decrease in total number of cells (Fig. 3A) . In the control condition, cell growth during 24-h repair allowed the recovery of a number of cells similar to that measured before wounding (98.4 Ϯ 3.9 and 98.2 Ϯ 4.8% in NuLi and CuFi in BEGM EGF-free , respectively, n ϭ 10). Cell growth was, however, significantly slower in the ). TNF-␣ pretreatments were administered in BEGM ϩEGF , and the wound-closure rate was evaluated in BEGM ϩEGF (6-h repair, B) or BEGM EGF-free (BEGM ϩEGF replaced by BEGM EGF-free at T0 after wounding, 18 h of repair, C) and compared with control, untreated monolayers. Repair rate stimulation by TNF-␣ was then reported as a percentage of control monolayers in BEGM ϩEGF (B, n ϭ 6) and BEGM EGF-free (C, n ϭ 6). *(difference compared with NuLi Ctl): P Ͻ 0.04; presence of TNF-␣ (88.5 Ϯ 3.0 and 85.7 Ϯ 4.9% of the initial number of NuLi and CuFi after 24 h of repair, respectively, P Ͻ 0.008).
To focus on cell migration (and avoid any significant cell proliferation), smaller wounds were produced in time-lapse experiments (Fig. 3B) . Quantification of the mean cell migration rate from single, randomly selected cells tracked on each side of the wound edge revealed that TNF-␣ exposure accelerated NuLi cell migration (111 Ϯ 13 m/h) compared with nontreated cells (54 Ϯ 13 m/h, P Ͻ 0.05). CuFi cell migration (36 Ϯ 7 m/h) was also stimulated by TNF-␣ (62 Ϯ 10 m/h, P Ͻ 0.01). Our data suggested that stimulation of the wound-healing rate observed in the presence of TNF-␣ might derive from upregulation of bronchial cell migration, despite reduced cell growth. Subsequent experiments were then designed to clarify the mechanisms and signaling pathways involved in TNF-␣-induced repair stimulation.
Role of metalloproteinases in the regulation of bronchial wound healing by TNF-␣. Indirect activation of different types of metalloproteinases (MMPs and ADAMs) after TNF-␣ stimulation has been reported (2, 15, 65) . These proteases are involved in cell migration and repair, by degrading the ECM and by releasing and activating growth factors (including EGF) in epithelial cells (8, 14, 27, 39, 43, 64) . We then decided to evaluate the relationship between TNF-␣ responses and metalloproteinase activity during repair, in NuLi and CuFi cells, in the absence of exogenous EGF prestimulation. MMPs were assessed by gelatinase zymography, which showed that 92-kDa proform MMP-9 and mature 86-kDa MMP-9 were virtually undetectable in conditioned medium collected from nontreated NuLi and CuFi monolayers (Fig. 4A) . Interestingly, TNF-␣ highly stimulated pro-MMP-9 and MMP-9 release in intact and wounded NuLi and CuFi monolayers (Fig. 4A , n ϭ 6, P Ͻ 0.008). This effect was partially reversed by GM6001, a broad-spectrum metalloproteinase inhibitor (Fig. 4A , P Ͻ 0.04). The role of metalloproteinase activity in TNF-␣-induced bronchial repair stimulation was then examined. We observed that GM6001 severely reduced NuLi and CuFi wound-healing rates in basal (Fig. 4B , GM, P Ͻ 0.02) as well as in TNF-␣-stimulated (GMϩTNF-␣, P Ͻ 0.002) conditions.
Involvement of secreted EGF in TNF-␣-induced woundrepair stimulation. Because metalloproteinases are involved in growth factor release in many cell types (8, 43, 64) , we decided to study EGF shedding, a major component of NuLi and CuFi repair (58) , in basal and TNF-␣ conditions. As illustrated in Fig. 5A , EGF expression in the conditioned medium of NuLi and CuFi was increased significantly after exposure to TNF-␣ (3.1-and 2.5-fold increment in NuLi and CuFi, respectively, n ϭ 5, P Ͻ 0.005). We then decided to examine the role of secreted EGF in TNF-␣-induced repair stimulation. As illustrated in Fig. 5B , the addition of an EGF antibody (EGF-Ab, 5 g/ml), to titrate shed EGF significantly reduced the basal wound-healing rate in both NuLi (from 33.9 Ϯ 5.0 ϫ 10 3 to 20.2 Ϯ 4.8 ϫ 10 3 m 2 /h in the presence of EGF-Ab, n ϭ 10, P Ͻ 0.0005) and CuFi monolayers (from 18.7 Ϯ 4.0 ϫ 10 3 to 7.6 Ϯ 2.0 ϫ 10 3 m 2 /h with EGF-Ab, n ϭ 10, P Ͻ 0.002). Moreover, TNF-␣ stimulation was completely abolished by EGF-Ab in NuLi and CuFi cells (EGF-Ab vs. EGFAbϩTNF-␣, Fig. 5B ). These data indicated that the stimulatory effect of TNF-␣ depends on EGF secreted by bronchial cells.
Coupling between the EGFR and TNF-␣ pathways during bronchial repair.
To demonstrate that TNF-␣ treatment may result in secondary activation of EGFR after EGF shedding, we examined the level of EGFR phosphorylation, in NuLi and CuFi extracts, treated or not for 15 min with TNF-␣ or EGF (positive control). TNF-␣ elicited 1.6-and 1.3-fold increases in the pEGFR/EGFR ratio in NuLi and CuFi cells, respectively (Fig. 6A , n ϭ 9, P Ͻ 0.03), similarly to positive control EGF stimulation (Fig. 6A) . Note that this TNF-␣ treatment did not modify EGFR expression in NuLi and CuFi cells. The involvement of EGFR activation in bronchial repair stimulation by TNF-␣ was then investigated. As reported in Fig. 6B , the erbB1 and erbB2 EGFR inhibitors AG-1478 and AG-825 (AG) significantly inhibited the basal wound-healing rate in NuLi (32.6 Ϯ 7.1 ϫ 10 3 to 17.7 Ϯ 6.7 ϫ 10 3 m 2 /h after EGFR inhibition, n ϭ 7, P Ͻ 0.002) and CuFi (20.8 Ϯ 5.2 ϫ 10 3 to 8.8 Ϯ 1.5 m 2 /h, n ϭ 7, P Ͻ 0.03). In addition, EGFR inhibition completely blocked TNF-␣-induced stimulation (Fig. 6B) . Taken together, the results reported in Figs. 5 and 6 indicate possible cross-talk between TNF-␣ stimulation and the EGF/EGFR pathway.
Relationship between TNF-␣ stimulation and K ϩ channel function during bronchial repair. Our previous work demonstrated that alveolar and bronchial repair as well as cell migration and proliferation depended on K ϩ channel activity, coupled to EGFR signaling (57, 58) . We then decided to investigate the relationship between TNF-␣ stimulation and K ϩ channel activities. First, the effect of TNF-␣ on basolateral K ϩ currents of NuLi and CuFi cell layers was evaluated in I sc experiments in an Ussing chamber (Fig. 7A) . Upon current stabilization, clofilium and glibenclamide were applied at the basolateral membrane (Fig. 7A) to block KvLQT1 and K ATP channels, responsible for a major part of basolateral K ϩ permeability in basal conditions (58) . Clofilium-and glibenclamide-sensitive basolateral K ϩ currents (I ClofiGlib ) were compared in the control condition and after acute (10 min) or chronic (24 h) stimulation by TNF-␣. Acute exposure to TNF-␣ slightly increased I ClofiGlib (0.8 Ϯ 0.2 A/cm 2 increment, P Ͻ 0.02, n ϭ 5, data not shown) through NuLi layers, whereas it failed to significantly stimulate CuFi I ClofiGlib currents (0.2 Ϯ 0.3 A/cm 2 , NS, n ϭ 10, data not shown). Longer exposure to TNF-␣ (24-h pretreatment, Fig. 7A ) resulted in significant stimulation of K ϩ currents, as seen in representative I sc traces, through NuLi (Fig. 7A, top) and CuFi (Fig. 7A , bottom) in control (Fig. 7A, left) and TNF-␣ (Fig. 7A, right) conditions. We recorded mean 1.7 Ϯ 0.4 A/cm 2 (P Ͻ 0.01) and 3.1 Ϯ 0.6 A/cm 2 (P Ͻ 0.0006) increases in I ClofiGlib through NuLi and CuFi, respectively, after TNF-␣ application. Finally, the role of K ϩ channel activity in TNF-␣-stimulated wound healing was explored. The combination of clofilium (5 M), glibenclamide (100 M), and TRAM-34 (5 M), respectively inhibitors of KvLQT1, K ATP , and KCa3.1 (which also participate in repair processes, Ref. 58), severely reduced NuLi (8.1 Ϯ 1.6 ϫ 10 3 m 2 /h, n ϭ 8, P Ͻ 0.004) and CuFi (7.7 Ϯ 1.3 ϫ 10 3 m 2 /h, n ϭ 8, P Ͻ 0.0002) basal wound healing (Fig. 7B) . K ϩ channel inhibition also abolished the woundrepair stimulation evoked by TNF-␣ in both NuLi and CuFi monolayers (Fig. 7B) . Altogether, these data indicated that K ϩ channel upregulation by TNF-␣ is involved in TNF-␣-induced stimulation of bronchial repair.
Physiological impact of TNF-␣ on human primary non-CF and CF airway epithelial cells.
After the identification of TNF-␣-stimulated wound repair in bronchial cell lines, we assessed the physiological impact of this cytokine in primary epithelial cells, isolated from human non-CF and CF airway tissues. We first confirmed that wound repair was slower in CF than in non-CF monolayers (Fig. 8) . Furthermore, TNF-␣ markedly stimulated both non-CF (from 37.7 Ϯ 8. 
DISCUSSION
Proinflammatory cytokines exert opposing actions on several cellular responses, including initiation and propagation of inflammation, as well as the regulation of proliferation and migration processes. We thus postulated that TNF-␣, a major cytokine in CF airways, could modulate the repair mechanisms of bronchial epithelia after injury. Our results demonstrated, for the first time, that acute and chronic exposure to TNF-␣ stimulated wound-healing rates in NuLi and CuFi cell lines as well as in primary human non-CF and CF airway cell monolayers. Although cell growth during repair was reduced by TNF-␣, upregulation of bronchial cell migration was observed and was probably responsible for acceleration of the woundclosure rate. Our data indicated that cross-talk between the TNF-␣ and EGFR transduction pathways may be involved in this stimulation. In addition to the EGF response, K ϩ channel function seems important for TNF-␣-stimulated bronchial repair. Besides its well-known action on propagation of the inflammatory response, leading to progressive damage of the EGF-BPE-free , in the presence or absence of TNF-␣ (40 ng/ml) and/or GM6001 (GM, 25 M), before conditioned medium collection. Pro-MMP-9 and MMP-9 in these conditioned media were then assessed by gelatin substrate zymography (n ϭ 6). A representative gelatin zymograph is presented (note that the gel image has been inverted for illustration purposes, i.e., dark background with light bands turned into light background with dark bands). B: NuLi and CuFi cell monolayers were injured mechanically, and the wound-healing rate (m 2 /h) was measured after 18 h (BEGM EGF-free ) in control monolayers (Ctl) and in monolayers treated with TNF-␣ (40 ng/ml, TNF-␣) and/or GM6001 (GM, 25 M). *P Ͻ 0.02 (paired t-test), n ϭ 12.
respiratory epithelium, TNF-␣ thus controls the repair processes of CF airway epithelia.
Regulation of repair mechanisms by the proinflammatory cytokine TNF-␣. Our wound-healing assays first confirmed, as we reported previously (58) , that the repair rate in CuFi was slower than in NuLi. The repair mechanisms in NuLi and CuFi monolayers were compared more extensively in our previous paper (58) , which documented a lower CuFi migration rate associated with reduced expression and function of K ϩ channels as well as weaker EGF responses during repair. Consistently, a greater increase in the wound-healing rate was observed after EGF stimulation in NuLi than in CuFi cells. The basic CFTR defect could also be involved in delayed CF repair, as indicated in recent studies by Schiller et al. (50) and our laboratory (56) . Moreover, wound-healing assays in human primary CF airway epithelial cells have confirmed a delay in repair in CF compared with non-CF monolayers (Fig. 8) .
Our experiments also show that acute TNF-␣ accelerated both NuLi and CuFi bronchial wound healing (Fig. 1) . Because chronic inflammation favors epithelial injury, we postulated that chronic exposure to TNF-␣ might decrease epithelial repair capacity. However, we did not detect significant TNF-␣ cytotoxicity on confluent bronchial monolayers during repair. Moreover, TNF-␣ pretreatment had a greater stimulatory effect on wound healing than acute exposure to TNF-␣ (Fig. 2) . Our data also disclosed (Fig. 3B ) that cell migration, the first process engaged after injury, was accelerated by TNF-␣. We noted, however, that TNF-␣ stimulation of the migration rate was lower in CuFi than in NuLi (compare the slopes in Fig.   Fig. 5 . Role of secreted EGF in TNF-␣-induced bronchial wound-repair stimulation. A: NuLi and CuFi cell monolayers were treated or not for 24 h with TNF-␣ (40 ng/ml, in BEBM) before conditioned medium collection. Pro-EGF and EGF expression, in these conditioned media, was then analyzed by Western blotting, with anti-EGF antibody (Ab). A representative immunoblot is reported with the mean EGF/pro-EGF ratio (in % of Ctl, n ϭ 5, P Ͻ 0.005). B: NuLi and CuFi cell monolayers were injured mechanically, and the wound-healing rate (m 2 /h) was measured after 18 h (in BEGM EGF-free ) in control monolayers (Ctl) and in monolayers treated with TNF-␣ (40 ng/ml, TNF-␣) and/or EGF-Ab (titrating shed EGF, EGF-Ab, 5 g/ml) *P Ͻ 0.04 (paired t-test), n ϭ 10. EGF-BPE-free before protein extraction and exposed or not for 15 min to TNF-␣ (40 ng/ml) or EGF (25 ng/ml, positive control). Representative immunoblots as well as the mean pEGFR/EGFR ratio (presented as % of control nontreated cells) are reported for TNF-␣ and EGF conditions. NuLi *P Ͻ 0.007, CuFi *P Ͻ 0.03 (paired t-test), n ϭ 8. B: NuLi and CuFi monolayers were injured mechanically, and the rate of wound healing (in m 2 /h) was measured after 18 h (BEGM EGF-free ) in control (Ctl) and TNF-␣ (40 ng/ml, TNF-␣) and/or erbB1 and erbB2 inhibitor (AG-1478, 10 M) ϩ (AG-825, 10 M) (AG)-treated monolayers. *P Ͻ 0.002 (paired t-test), n ϭ 7. 3B). Consistently, wound healing remained lower in CuFi than in NuLi after TNF-␣ stimulation (Fig. 1) . We also saw that cell growth in repairing monolayers was reduced by TNF-␣ (Fig.  3A) . Thus the observed TNF-␣ stimulation of wound closure is most probably consecutive to enhanced cell migration.
Although 5 to 100 ng/ml TNF-␣ concentrations are commonly used in cell proliferation and migration as well as in epithelial repair assays (2, 10, 15, 55, 59) , the 40 ng/ml TNF-␣ dose tested in our study is fairly high. We noted, however, that 5 ng/ml TNF-␣ was sufficient to stimulate bronchial wound healing. This concentration is similar to the TNF-␣ levels detected in the bronchoalveolar lavage (BAL) of patients with acute respiratory distress syndrome (46, 54) or pneumonia (19) , in BAL or sputum from patients with CF (9, 37), as well as in BAL from mice infected with Streptococcus pneumoniae (5) . In fact, from cytokine measurements in BAL, it is difficult to extrapolate to which TNF-␣ dose epithelial cells are exposed locally. In infected mice, for example, a maximum of 5 ng/ml TNF-␣ was found in BAL, whereas levels up to 34 ng/ml were detected in lung tissues (5) . Our findings thus indicate that TNF-␣, at concentrations close to those encountered in several lung pathologies, could regulate the repair processes of airway epithelia.
The literature reports some paradoxical data on TNF-␣ as a regulator of proliferative and migratory responses. Our results, which highlight that TNF-␣ decreases NuLi and CuFi cell growth, are consistent with inhibition of alveolar cell proliferation (6), whereas proliferative effects of TNF-␣ have been noted in other cell types (2, 15, 59 ). In addition, several studies have also demonstrated that TNF-␣ upregulates the migration of epithelial cells, including mammary and alveolar cells (15, 41) , in agreement with our time-lapse experiments. Although stimulation of cell migration by TNF-␣ may promote airway epithelial regeneration, other mechanisms, including cell proliferation and differentiation, are necessary for effective repair. Further investigation into the effect of TNF-␣ on these repair processes in vivo will be necessary to define the overall impact of TNF-␣ on CF airway regeneration after injury.
Role of metalloproteinase and EGF release in TNF-␣-induced wound-healing stimulation.
Several experiments were conducted to elaborate the mechanisms underlying TNF-␣-mediated stimulation of bronchial wound-healing and cellmigration rates. Our results support a role of MMPs in woundhealing stimulation after TNF-␣ exposure. Indeed, gelatin zymography revealed pro-and active-MMP-9 release after TNF-␣ exposure in NuLi and CuFi cells (Fig. 4A) , in agreement with other studies in skin and mammary epithelial cells (15, 65) . TNF-␣ signaling has been shown to mediate secondary activation of other members of the metalloproteinase family, including ADAM-17 in hepatocytes (2) and the metalloela- Fig. 7 . Coupling between K ϩ channel activity and TNF-␣ stimulation during bronchial wound healing. A: NuLi and CuFi cells were cultured on permeant filters at the air-liquid interface and treated or not for an additional 24 h on the basolateral side with TNF-␣ (40 ng/ml), before short-circuit current (Isc). Upon current stabilization, clofilium and glibenclamide were applied, to evaluate KvLQT1 and KATP currents (IClofiGlib). Representative Isc traces are reported for each condition (NuLi Ctl, NuLi TNF-␣, CuFi Ctl, and CuFi TNF-␣). B: NuLi and CuFi cell monolayers were injured mechanically, and the rate of wound healing (in m 2 /h) was measured after 18 h (in BEGM EGF-free ) in control monolayers (Ctl) and in monolayers treated with TNF-␣ (40 ng/ml, TNF-␣) and/or clofilium (5 M), glibenclamide (100 M), and TRAM-34 (5 M), applied in combination (Kinh). *P Ͻ 0.04 (paired t-test), n ϭ 8. Fig. 8 . Wound-repair stimulation by TNF-␣ in human primary non-CF and CF airway epithelial cells. Airway cells, isolated from non-CF (n ϭ 5) and CF patients (n ϭ 5), in primary culture, were injured mechanically, and the rate of wound healing (in m 2 /h) was measured after 6 h in control monolayers (Ctl) and in monolayers treated with TNF-␣ (40 ng/ml, TNF-␣). *P Ͻ 0.04, (paired t-test).
stase MMP-12 in human bronchial cells (38) . However, our casein zymography experiments did not disclose any MMP-12 activity in NuLi and CuFi (data not shown).
Our results also indicated that metalloproteinases are crucial for stimulation of the wound-healing rate after TNF-␣ treatment. Indeed, GM6001 severely inhibited basal repair and almost completely prevented TNF-␣-induced repair (Fig. 4B) . The involvement of MMPs, and particularly MMP-9, in airway wound repair and cell migration has already been reported in other studies (11, 39) . In contrast, it has been shown that MMP-2 and MMP-9 in conditioned medium from tracheal cartilage inhibit the adherence and proliferation of tracheal epithelial cells, an effect prevented by GM6001 (53) .
In addition to their role in ECM degradation and migration processes, MMPs and ADAMs are also involved in the release and maturation of cell surface pro-EGFR ligands into their active forms in many cell types (2, 8, 29, 33, 43, 64) . Our data demonstrated for the first time that TNF-␣ treatment induced a subsequent decrease of the inactive pro-EGF form and evoked active EGF shedding by NuLi and CuFi cells (Fig. 5 ). In addition, the titration of released EGF, with an EGF-Ab, significantly reduced the basal wound-healing rate (Fig. 5B ) and completely reversed TNF-␣-induced stimulation, proving the role of EGF shedding in the regulation of bronchial repair by TNF-␣. Beside growth factors, TNF-␣ could also induce secondary release of other cytokines, such as IL-1␤, which has been shown to stimulate wound repair (25) . We did not, however, observe any inhibitory effect of an IL-1␤ antibody, to titrate potentially secreted IL-1␤, on basal as well as TNF-␣-stimulated bronchial repair (data not shown).
Cross-talk between the TNF-␣ and EGFR pathways. Our data indicate EGFR transactivation after TNF-␣ exposure. Indeed, wound closure induced by TNF-␣ was prevented by both titrating-released EGF with an EGF antibody (Fig. 5B) and by inhibiting erbB1 and erbB2 EGFR tyrosine kinase activity (Fig. 6B) . In addition, our Western blotting experiments revealed an increased pEGFR/EGFR ratio after 15-min TNF-␣ stimulation, indicating secondary EGFR activation by TNF-␣ (Fig. 6A) . Such EGFR transactivation is a common phenomenon observed in the presence of inflammatory products, the virulence factor lipopolysaccharide, or oxidative stress in the airways (12, 36) and other epithelial cells (15, 62) . However, our study demonstrated, for the first time, cross-talk between the TNF-␣ and EGFR pathways during wound repair in CF airway monolayers.
Role of K ϩ channels in TNF-␣-induced wound-healing stimulation. Ion channels, and in particularly K ϩ channels, control the mitogenic and motogenic properties of several cell types, via changes in cell volume, membrane potential, and [Ca 2ϩ ] i , or by directly interacting with proteins of the migratory machinery, such as integrins (1, 51) . In the lungs, among over 30 different K ϩ channels (4), KvLQT1 and K ATP , which are responsible for a major part of basolateral K ϩ permeability, are essential in respiratory epithelial repair processes (57, 58) . In addition, KCa3.1 channels could be stimulated after injury and may play a complementary role, with KvLQT1 and K ATP channels, in basal bronchial repair (58) . We discovered that simultaneous application of clofilium, glibenclamide, and TRAM-34, inhibitors of KvLQT1, K ATP , and KCa3.1, respectively, completely prevented TNF-␣-induced stimulation (Fig.  7B) . TRAM-34 is a specific KCa3.1 inhibitor, but clofilium and glibenclamide could exert nonspecific effects. Indeed, CFTR and K ATP are both inhibited by glibenclamide. Furthermore, the CFTR channel could be engaged in bronchial repair, as indicated by recent data from Scott O'Grady's group (50) and our laboratory (56) . However, our previous study (58) showed that glibenclamide, inhibiting basolateral K ϩ current, significantly reduced wound repair, not only in NuLi but also in CuFi cells (lacking CFTR), clearly demonstrating K ATP channel involvement in basal wound repair. Clofilium has been used frequently in airway epithelia to study KvLQT1 channels (18, 20, 42, 44) ; however, this drug is also a blocker of Twikrelated acid-sensitive K ϩ (TASK) channels (31) . Because higher clofilium concentrations (ϳ100 M) are necessary to inhibit TASK channels (31, 47) , we are quite confident that the suppressive effect of 5 M clofilium on wound repair (Fig. 7) is mainly due to its influence on KvLQT1. Moreover, we verified that chromanol 293B, which inhibits KvLQT1 (7, 26, 34, 45) but not TASK channels (24, 31) , also reduced basolateral K ϩ currents and wound repair (data not shown). Interestingly, we found that 24-h treatment with TNF-␣ stimulated basolateral KvLQT1 and K ATP K ϩ currents (Fig.  7A ), which could be explained by increased K ϩ channel expression or trafficking to the membrane. In fact, conflicting results have been published describing the impact of TNF-␣ on K ϩ channel activity and expression. For example, chronic TNF-␣ treatment evoked Kv1.3 but downregulated Kir2.1 expression in the brain (60) . We determined previously that K ϩ currents (57, 58) and expression (57) were upregulated by EGF, and the present study demonstrated that TNF-␣ evoked secondary EGF shedding (Fig. 5A) . Thus it could be postulated that TNF-␣-induced regulation of K ϩ channels could be indirectly mediated by EGFR signaling. This hypothesis, however, needs to be verified. Fig. 9 . Schematic model of TNF-␣ action on bronchial epithelial repair. In this model, we propose that the inflammatory cytokine TNF-␣ induces secondary MMP-9 and EGF release, followed by EGFR activation, thus stimulating NuLi and CuFi cell migration and wound healing. Note that MMP could also be directly involved in repair regulation through extracellular matrix degradation. Our results also indicate a relationship between TNF-␣ stimulation and K ϩ channel function. In contrast, cell proliferation is reduced in the presence of TNF-␣, suggesting a complex role of this proinflammatory cytokine in epithelial injury and repair processes.
Overall, our results revealed that TNF-␣ stimulated NuLi and CuFi bronchial wound repair as well as human primary non-CF and CF cell monolayers. Our findings also showed that TNF-␣ induced secondary release of MMP-9 and EGF, followed by EGFR activation as well as an increase of K ϩ currents, as reported in our integrated model (Fig. 9) . Moreover, TNF-␣-stimulated wound closure was prevented by metalloproteinase inhibition, EGF titration, EGFR tyrosine kinase suppression, and K ϩ channel blockade. Our data also disclose that TNF-␣ elicited an opposite effect on cell migration (upregulation) and cell growth (downregulation).
Our study thus demonstrates that the role of TNF-␣ is far more complex than previously assumed. Intervention in CF airway inflammation may thus result in a beneficial action by controlling the inflammatory response but, on the other hand, could have some deleterious side-effects on innate immunity or some repair mechanisms. Several anti-inflammatory therapies have been tested in patients with CF. Among them, it has been postulated that anti-TNF-␣ therapies, developed for the management of rheumatoid arthritis, may be helpful in patients with CF (13, 16) . In fact, whereas some studies on antiinflammatory therapies have yielded encouraging results, others have failed to show an improvement in lung function or caused unacceptable adverse events (3, 16, 23) . In fact, in light of our results, we think that further investigation is necessary to elaborate the overall effect of TNF-␣ and anti-TNF-␣ therapies on lung injury and repair.
